Brief: Caribou Biosciences Initiates Dose Expansion Portion Of CB-010 ANTLER Phase 1 Trial In Second-Line LBCL Patients

Caribou Biosciences

29/03/2023 15:13

March 29 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES INITIATES DOSE EXPANSION PORTION OF
CB-010
ANTLER PHASE 1 TRIAL IN SECOND-LINE LBCL PATIENTS
    * CARIBOU BIOSCIENCES INC - NEXT ANTLER UPDATE PLANNED FOR
H2 2023
    * CARIBOU BIOSCIENCES - IN ANTLER DOSE ESCALATION, CB-010
WAS WELL
TOLERATED AT ALL 3 DOSE LEVELS EVALUATED, DEMONSTRATING AN
ENCOURAGING SAFETY PROFILE

Source text for Eikon:  ID:nGNX4YJWDJ 
Further company coverage:  CRBU.O